Press "Enter" to skip to content

Bioaffinity Technologies With UV Detectable Lung Cancer Cell Technology Files S-1 With SEC

Bioaffinity Technologies files Form S-1, Registration for Securities / Prospectus, with SEC on September20, 2023. The company identifies Cypath Lung (trademarked) technology as using “a…
This content is viewable by members only. Visit MY ACCOUNT on the top menu to log in or to register for a 30 day free trial or purchase a subscription for UV Reporter 1 Year Single Membership or UV Reporter 1 Year Group Membership - $189 for first member and $25 for each additional member.